These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 29280080)

  • 1. Correction to: Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms.
    Klöppel G; La Rosa S
    Virchows Arch; 2018 Mar; 472(3):515. PubMed ID: 29280080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms.
    Klöppel G; La Rosa S
    Virchows Arch; 2018 Mar; 472(3):341-349. PubMed ID: 29134440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods.
    Tang LH; Gonen M; Hedvat C; Modlin IM; Klimstra DS
    Am J Surg Pathol; 2012 Dec; 36(12):1761-70. PubMed ID: 23026928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification.
    Yang Z; Tang LH; Klimstra DS
    Am J Surg Pathol; 2011 Jun; 35(6):853-60. PubMed ID: 21566513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastroenteropancreatic neuroendocrine neoplasms: historical context and current issues.
    Yang Z; Tang LH; Klimstra DS
    Semin Diagn Pathol; 2013 Aug; 30(3):186-96. PubMed ID: 24144288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tissue heterogeneity contributes to suboptimal precision of WHO 2010 scoring criteria for Ki67 labeling index in a subset of neuroendocrine neoplasms of the pancreas].
    Liszka Ł
    Pol J Pathol; 2016; 67(4):318-331. PubMed ID: 28547959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction to: A Limiting Channel Capacity of Visual Perception: Spreading Attention Divides the Rates of Perceptual Processes.
    Lappin JS; Seiffert AE; Bell HH
    Atten Percept Psychophys; 2020 Oct; 82(7):3775-3776. PubMed ID: 32715440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA methyltransferases 1, 3a, and 3b overexpression and clinical significance in gastroenteropancreatic neuroendocrine tumors.
    Rahman MM; Qian ZR; Wang EL; Yoshimoto K; Nakasono M; Sultana R; Yoshida T; Hayashi T; Haba R; Ishida M; Okabe H; Sano T
    Hum Pathol; 2010 Aug; 41(8):1069-78. PubMed ID: 20381114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma.
    Vartanian RK; Weidner N
    Am J Pathol; 1994 Jun; 144(6):1188-94. PubMed ID: 7515558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
    Janson ET; Sorbye H; Welin S; Federspiel B; Grønbæk H; Hellman P; Ladekarl M; Langer SW; Mortensen J; Schalin-Jäntti C; Sundin A; Sundlöv A; Thiis-Evensen E; Knigge U
    Acta Oncol; 2014 Oct; 53(10):1284-97. PubMed ID: 25140861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recent advances in gastroenteropancreatic neuroendocrine tumor pathology].
    Sasano H; Kasajima A
    Gan To Kagaku Ryoho; 2013 Jul; 40(7):833-7. PubMed ID: 23863722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms.
    Klöppel G
    Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S1-16. PubMed ID: 22005112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
    Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
    Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Confirming statements about pictures of natural scenes: evidence of the processing of gist from eye movements.
    Underwood G; Crundall D; Hodson K
    Perception; 2005; 34(9):1069-82. PubMed ID: 16245486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction to: Gamma-delta (γδ) T cells: friend or foe in cancer development?
    Zhao Y; Niu C; Cui J
    J Transl Med; 2018 May; 16(1):122. PubMed ID: 29739416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction to: Application of a Novel 'Make and Test in Parallel' Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects.
    Cheeti S; Hou HH; Nelson E; Walker H; Chen B; Morley R; Gates M; Musib L; Girish S; Sahasranaman S; Liu L
    Pharm Res; 2018 Oct; 35(12):244. PubMed ID: 30367284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erratum.
    J Phys Act Health; 2011 Nov; 8(8):1175. PubMed ID: 28796592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and therapeutic role of endoscopy in gastroenteropancreatic neuroendocrine neoplasms.
    Attili F; Capurso G; Vanella G; Fuccio L; Delle Fave G; Costamagna G; Larghi A
    Dig Liver Dis; 2014 Jan; 46(1):9-17. PubMed ID: 23731843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories.
    Milione M; Maisonneuve P; Spada F; Pellegrinelli A; Spaggiari P; Albarello L; Pisa E; Barberis M; Vanoli A; Buzzoni R; Pusceddu S; Concas L; Sessa F; Solcia E; Capella C; Fazio N; La Rosa S
    Neuroendocrinology; 2017; 104(1):85-93. PubMed ID: 26943788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
    Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
    BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.